Overview

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cocaine
Galantamine
Criteria
Inclusion Criteria:

- Male and females, between the ages 21 and 50

- Fulfill criteria for past cocaine dependence

- No cocaine use for the past 30 days

- No other current dependence or abuse of other drugs or alcohol

- No current medical problems and normal ECG

- Not pregnant,nor breast feeding,

- Using acceptable birth control methods.

Exclusion Criteria:

- Current major psychiatric illness including mood, psychotic or anxiety disorders

- History of major medical illnesses; including asthma or chronic obstructive lung
disease, history or current gastrointestinal ulcer, hepatic or renal impairment and
cardiac rhythm disturbances

- Use of other medications including,drugs that slow heart rate

- Known allergy to galantamine